

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

X



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[Back](#)

[Medical Oncology & Treatment](#)  
[Learn About Cancer & Treatment](#)

## ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

## FOR THE MEDIA



**Jacqueline F. Bromberg, MD, PhD**

[Breast Medical Oncologist \(#about-me\)](#)



**Areas of Expertise**

**Conditions I Treat**

- Breast cancers and conditions
- Inflammatory breast cancer (IBC)

 [Dr. Bromberg's Office Information \(#contact-and-location\)](#)



Languages: English & French

## Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

[Call 646-497-9064](#)

[Make an appointment](#)

## Get to Know Me

I am a physician-scientist with 25 years of clinical expertise caring for people with breast cancer. I work as part of a team of breast cancer specialists who see patients in New York City and in Monmouth, New Jersey.

One of my primary objectives is to educate my patients and support them so they can make informed decisions about their care. I take the time to explain the clinical research leading to our treatment recommendations. For example, when patients first meet with me, they often ask how they can improve their tolerance and response to treatment. We discuss the evidence supporting the positive role of exercise and maintaining a normal body mass index (BMI). It's important for patients to have control over their care and well-being, and these interventions may result in improved outcomes.

Read more +

### What I Do at MSK

I'm a breast medical oncologist, which is a cancer doctor who specializes in breast cancer.

- Attending Physician

## Areas of Expertise

### Conditions I Treat

- Breast cancers and conditions
- Inflammatory breast cancer (IBC)

## Education & Honors

### Education

- MD, University of North Carolina School of Medicine
- PhD, University of North Carolina, Department of Genetics

### Residencies

- Internal Medicine - Barnes Hospital

### Fellowships

- Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center

### Board Certifications

- Internal Medicine
- Medical Oncology

## Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage](#) .

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](#).

## Make an Appointment

### New Patients

Scheduling an appointment is easy. Click or call [646-497-9064](#) — we're available 24 hours a day, 7 days a week

[Make an Appointment](#)

### Current Patients

Request an appointment by calling your Care Team or messaging them in [MSK MyChart](#).

## Contact and Location

### Office Phone

 [646-888-4620](#)

### Location

 New York, NY

 Middletown, NJ

[Evelyn H. Lauder Breast Center](#)

 300 East 66th Street  
Floors 1 - 4

New York, NY 10065

[Get Directions](#)

#### [Memorial Sloan Kettering Monmouth](#)



480 Red Hill Road

Middletown, NJ 07748

[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations](#) .

## Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

[See all Breast Medicine Service doctors](#) ([https://www.mskcc.org/doctor#f:Departments=\[Medicine,Division of Solid Tumor Oncology,Breast Medicine Service\]](https://www.mskcc.org/doctor#f:Departments=[Medicine,Division of Solid Tumor Oncology,Breast Medicine Service]))

## Clinical Trials

- Clinical Trials Co-Investigated by Dr. Bromberg

- [A Phase II Study Evaluating Stereotactic Body Radiotherapy plus Standard Therapy versus Standard Therapy Alone in Patients with Oligometastatic Breast Cancer or Lung Cancer](#)



## Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

[Search clinical trials \(<https://www.mskcc.org/cancer-care/clinical-trials>\)](https://www.mskcc.org/cancer-care/clinical-trials)

## Research and Publications

Sansone P, Savini C, Kurelac I, Chang Q, Amato LB, Strillacci A, Stepanova A, Iommarini L, Mastroleo C, Daly L, Galkin A, Thakur BK, Soplop N, Uryu K, Hoshino A, Norton L, Bonafé M, Cricca M, Gasparre G, Lyden D, Bromberg J. Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. *Proc Natl Acad Sci U S A*. 2017 Oct 24;114(43):E9066-E9075. doi: 10.1073/pnas.1704862114. Epub 2017 Oct 11. Erratum in: *Proc Natl Acad Sci U S A*. 2017 Nov 13;: PMID: 29073103; PMCID: PMC5664494.

Sansone P, Berishaj M, Rajasekhar VK, Ceccarelli C, Chang Q, Strillacci A, Savini C, Shapiro L, Bowman RL, Mastroleo C, De Carolis S, Daly L, Benito-Martin A, Perna F, Fabbri N, Healey JH, Spisni E, Cricca M, Lyden D, Bonafé M, Bromberg J. Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles. *Cancer Res*. 2017 Apr 15;77(8):1927-1941. doi: 10.1158/0008-5472.CAN-16-2129. Epub 2017 Feb 15. Erratum in: *Cancer Res*. 2017 Oct 1;77(19):5438. PMID: 28202520; PMCID: PMC5392366.

Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S, Mark MT, Steiner L, Benito-Martin A, Lucotti S, Di Giannatale A, Offer K, Nakajima M, Williams C, Nogués L, Pelissier Vatter FA, Hashimoto A, Davies AE, Freitas D, Kenific CM, Ararso Y, Buehring W, Lauritzen P, Ogitani Y, Sugiura K, Takahashi N, Alečković M, Bailey KA,

Jolissant JS, Wang H, Harris A, Schaeffer LM, García-Santos G, Posner Z, Balachandran VP, Khakoo Y, Raju GP, Scherz A, Sagi I, Scherz-Shouval R, Yarden Y, Oren M, Malladi M, Petriccione M, De Braganca KC, Donzelli M, Fischer C, Vitolano S, Wright GP, Ganshaw L, Marrano M, Ahmed A, DeStefano J, Danzer E, Roehrl MHA, Lacayo NJ, Vincent TC, Weiser MR, Brady MS, Meyers PA, Wexler LH, Ambati SR, Chou AJ, Slotkin EK, Modak S, Roberts SS, Basu EM, Diolaiti D, Krantz BA, Cardoso F, Simpson AL, Berger M, Rudin CM, Simeone DM, Jain M, Ghajar CM, Batra SK, Stanger BZ, Bui J, Brown KA, Rajasekhar VK, Healey JH, de Sousa M, Kramer K, Sheth S, Baisch J, Pascual V, Heaton TE, La Quaglia MP, Pisapia DJ, Schwartz R, Zhang H, Liu Y, Shukla A, Blavier L, DeClerck YA, LaBarge M, Bissell MJ, Caffrey TC, Grandgenett PM, Hollingsworth MA, Bromberg J, Costa-Silva B, Peinado H, Kang Y, Garcia BA, O'Reilly EM, Kelsen D, Trippett TM, Jones DR, Matei IR, Jarnagin WR, Lyden D. Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. *Cell*. 2020 Aug 20;182(4):1044-1061.e18. doi: 10.1016/j.cell.2020.07.009. Epub 2020 Aug 13. PMID: 32795414; PMCID: PMC7522766.

Deipolyi AR, Riedl CC, Bromberg J, Chandarlapaty S, Klebanoff CA, Sofocleous CT, Yarmohammadi H, Brody LA, Boas FE, Ziv E. Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study. *J Vasc Interv Radiol*. 2018 Sep;29(9):1226-1235. doi: 10.1016/j.jvir.2018.04.018. Epub 2018 Aug 3. PMID: 30078647; PMCID: PMC6663492.

Yu HA, Perez L, Chang Q, Gao SP, Kris MG, Riely GJ, Bromberg J. A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. *J Thorac Oncol*. 2017 Jan;12(1):102-109. doi: 10.1016/j.jtho.2016.08.140. Epub 2016 Sep 6. PMID: 27613527; PMCID: PMC5552054.

Rodrigues G, Hoshino A, Kenific CM, Matei IR, Steiner L, Freitas D, Kim HS, Oxley PR, Scandariato I, Casanova-Salas I, Dai J, Badwe CR, Gril B, Tešić Mark M, Dill BD, Molina H, Zhang H, Benito-Martin A, Bojmar L, Ararso Y, Offer K, LaPlant Q, Buehring W, Wang H, Jiang X, Lu TM, Liu Y, Sabari JK, Shin SJ, Narula N, Ginter PS, Rajasekhar VK, Healey JH, Meylan E, Costa-Silva B, Wang SE, Rafii S, Altorki NK, Rudin CM, Jones DR, Steeg PS, Peinado H, Ghajar CM, Bromberg J, de Sousa M, Pisapia D, Lyden D. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. *Nat Cell Biol*. 2019 Nov;21(11):1403-1412. doi: 10.1038/s41556-019-0404-4. Epub 2019 Nov 4. PMID: 31685984; PMCID: PMC7354005.

Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, Psaila B, Kaplan RN, Bromberg JF, Kang Y, Bissell MJ, Cox TR, Giaccia AJ, Erler JT, Hiratsuka S, Ghajar CM, Lyden D. Pre-metastatic niches: organ-specific homes for metastases. *Nat Rev Cancer*. 2017 May;17(5):302-

317. doi: 10.1038/nrc.2017.6. Epub 2017 Mar 17. PMID: 28303905.

Gao SP, Chang Q, Mao N, Daly LA, Vogel R, Chan T, Liu SH, Bournazou E, Schori E, Zhang H, Brewer MR, Pao W, Morris L, Ladanyi M, Arcila M, Manova-Todorova K, de Stanchina E, Norton L, Levine RL, Altan-Bonnet G, Solit D, Zinda M, Huszar D, Lyden D, Bromberg JF. JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. *Sci Signal*. 2016 Mar 29;9(421):ra33. doi: 10.1126/scisignal.aac8460. PMID: 27025877; PMCID: PMC4950506.

Rajappa P, Cobb WS, Vartanian E, Huang Y, Daly L, Hoffman C, Zhang J, Shen B, Yanowitch R, Garg K, Cisse B, Haddock S, Huse J, Pisapia DJ, Chan TA, Lyden DC, Bromberg JF, Greenfield JP. Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells. *Clin Cancer Res*. 2017 Jun 15;23(12):3109-3119. doi: 10.1158/1078-0432.CCR-16-1508. Epub 2016 Dec 30. PMID: 28039266; PMCID: PMC5769921.

Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, Cotari J, Alpaugh ML, de Stanchina E, Manova K, Li M, Bonafe M, Ceccarelli C, Taffurelli M, Santini D, Altan-Bonnet G, Kaplan R, Norton L, Nishimoto N, Huszar D, Lyden D, Bromberg J. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. *Neoplasia*. 2013 Jul;15(7):848-62. doi: 10.1593/neo.13706. PMID: 23814496; PMCID: PMC3689247.

## Publications on PubMed

Visit PubMed for a full listing of Dr. Bromberg's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

[See all on PubMed \(<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=sloan-kettering%20AND%20Bromberg%20J>\)](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=sloan-kettering%20AND%20Bromberg%20J)

## Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical

application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Jacqueline F. Bromberg discloses the following relationships and financial interests:

- Magnet Biomedicine, Inc.  
Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#) . For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org) .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center